Back
Return
Biography

Dr. Colin Andrew Hutchison

University Hospital Birmingham and University of Birmingham, UK


Email: c.a.hutchison@bham.ac.uk


Qualifications

2008 Ph.D., University of Birmingham, UK

2000 MB, University of Leicester, UK


Publications

  1. Hutchison CA, Bridoux F, Fermand JP. Plasma exchange for the management of myeloma kidney. N Eng J Med. 2011 Sep 15;365(11):1061.
  2. Hutchison CA, Landgren O. Polyclonal Immunoglobulin Free Light Chains as a Potential Biomarker of Immune Stimulation and Inflammation. Clin Chem. 2011 Aug 11.
  3. Gondouin B, Hutchison CA. High cut-off dialysis membranes: current uses andfuture potential. Adv Chronic Kidney Dis. 2011 May;18(3):180-7.
  4. Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011 Jun;22(6):1129-36. Epub 2011 Apr 21.
  5. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011 Jun;79(12):1289-301. Epub 2011 Apr 13.
  6. Harding S, Provot F, Beuscart JB, Cook M, Bradwell AR, Stringer S, White D, Cockwell P, Hutchison CA. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1438. Epub 2011 Mar 15.
  7. Hutchison CA, Bridoux F. Renal impairment in multiple myeloma: time is of the essence. J Clin Oncol. 2011 Apr 10;29(11):e312-3; author reply e314. Epub 2011 Feb 22.
  8. Stringer S, Basnayake K, Hutchison C, Cockwell P.  Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney). Bone Marrow Research March 2011, article ID 493697.
  9. Grima DT, Airia P, Attard C, Hutchison CA. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Curr Med Res Opin. 2011 Feb;27(2):383-91.
  10. Hutchison CA, Pratt G. Free light-chains and renal disorders: when small is worse. Lancet. 2010 Oct 9;376(9748):1220.
  11. Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S, Hutchison CA, Cook M, Stoves J, Bradwell AR, Cockwell P. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol. 2010 Oct;63(10):884-7.
  12. CJ Ferro, NC Edwards, C Hutchison, P Cockwell, RP Steeds, CO Savage, JN Townend, L Harper.Does Immunosupressant medication Lower Blood Pressure and Arterial Stiffness in patients with Chronic kidney Disease? An observational Study.Hypertension research 2011 (34), 113-119.
  13. Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma. Curr Opin Nephrol Hypertens. 2010 Nov;19(6):550-5.
  14. Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S, Booth J, Howie AJ, Ghonemy T, Rajabali S, Roberts D, White L, Khan S, Morgan M, Cockwell P, Hutchison CA. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol. 2010 Nov;5(11):1977-80. Epub 2010 Jul 22.
  15. Basnayake K, Cockwell P, Hutchison CA. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009 Oct 1;361(14):1411-2; author reply 1412-3.
  16. Hutchison CA, Basnayake K, Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol. 2009 Nov;5(11):621-8. Epub 2009 Sep 29.
  17. Hutchison CA. Reduction of serum free light chains predict renal recovery. Ann Hematol. 2010 Jun;89(6):627-8.
  18. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54.
  19. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008 Dec;32(12):910-7.
  20. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov;3(6):1684-90.